title: Dermal tophus: a complication of gout in a kidney transplant recipient.
abstract: Gout is a chronic metabolic disease caused by disturbance of purine metabolism that leads to hyperuricemia. Hyperuricemia prevalence after renal transplant is reported as 19% to 84% in different studies. Tophaceous gout in renal transplant recipients is a consequence of increased hyperuricemia. Although tophus formation in skin and soft tissues is an indicator of chronic gout (also referred to as tophaceous gout), tophi may be the first sign of gout. In this study, we report a case of a 62-year-old male renal transplant recipient who had tophi as the first clinical sign of gout. After confirming gout diagnosis, cyclosporine was changed to sirolimus, and allopurinol was added to therapy to decrease uric acid levels. In conclusion, hyperuricemia is a common complication in renal transplant recipients. Presentation might be atypical, and diagnosis can be challenging.
authors.affiliation: From the Department of General Surgery, Baskent University Faculty of Medicine, Ankara, Turkey.
authors.forename: Ebru Hatice
authors.initials: EH
authors.lastname: Ayvazoglu Soy
authors.forename: Emre
authors.initials: E
authors.lastname: Karakaya
authors.forename: Arzu
authors.initials: A
authors.lastname: Karatas Togral
authors.forename: Aydincan
authors.initials: A
authors.lastname: Akdur
authors.forename: Gokhan
authors.initials: G
authors.lastname: Moray
authors.forename: Mehmet
authors.initials: M
authors.lastname: Haberal
mesh_terms: D000493:Allopurinol / Q000627:therapeutic use; D016572:Cyclosporine / Q000627:therapeutic use; D057915:Drug Substitution; D006073:Gout / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology*; D006074:Gout Suppressants / Q000627:therapeutic use; D006801:Humans; D033461:Hyperuricemia / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology*; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D016030:Kidney Transplantation / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D012307:Risk Factors; D020123:Sirolimus / Q000627:therapeutic use; D012867:Skin / Q000187:drug effects / Q000473:pathology*; D016896:Treatment Outcome
chemical_list: D006074:Gout Suppressants; D007166:Immunosuppressive Agents; D000493:Allopurinol; D016572:Cyclosporine; D020123:Sirolimus